← Back
$VYGR All transactions

Voyager Therapeutics, Inc.

A

$ Value

$0

Shares

32,250

Price

$0

Filed

Feb 10

Insider

Name

Jorgensen Nathan D.

Title

Chief Financial Officer

CIK

0001842523

Roles

Officer

Transaction Details

Transaction Date

2026-02-06

Code

A

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

156,084

Footnotes

Consists of shares of common stock issuable under an aggregate of 32,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. | This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

Filing Info

Accession No.

0001104659-26-012669

Form Type

4

Issuer CIK

0001640266

Jorgensen Nathan D.'s History

Date Ticker Type Value
2026-02-24 VYGR $18K
2026-02-06 VYGR A $0
2026-02-06 VYGR A $0
2025-10-03 VYGR $37K

Other Insiders at VYGR (90d)

Insider Bought Sold Last
Sandrock Alfred
President and CEO
$184K 2026-04-02
Jorgensen Nathan D.
Chief Financial Officer
$18K 2026-02-24
Swartz Robin
COO & CBO
$55K 2026-02-24
Carter Todd Alfred
Chief Scientific Officer
$41K 2026-02-24
Ferguson Toby
Chief Medical Officer
2026-02-06
Shiferman Gregory L.
SVP and General Counsel
2026-04-01